American International Group Inc. cut its stake in shares of Eli Lilly And Co (NYSE:LLY) by 1.3% in the 2nd quarter, Holdings Channel reports. The firm owned 299,304 shares of the company’s stock after selling 3,869 shares during the quarter. American International Group Inc.’s holdings in Eli Lilly And Co were worth $25,540,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of LLY. Global X Management Co. LLC lifted its position in Eli Lilly And Co by 10.6% during the first quarter. Global X Management Co. LLC now owns 20,268 shares of the company’s stock valued at $1,568,000 after acquiring an additional 1,945 shares during the last quarter. HL Financial Services LLC lifted its position in Eli Lilly And Co by 3.8% during the first quarter. HL Financial Services LLC now owns 82,453 shares of the company’s stock valued at $6,379,000 after acquiring an additional 2,986 shares during the last quarter. Hennessy Advisors Inc. purchased a new stake in Eli Lilly And Co during the first quarter valued at approximately $5,532,000. Daiwa Securities Group Inc. lifted its position in Eli Lilly And Co by 3.7% during the first quarter. Daiwa Securities Group Inc. now owns 46,417 shares of the company’s stock valued at $3,591,000 after acquiring an additional 1,644 shares during the last quarter. Finally, Meag Munich Ergo Kapitalanlagegesellschaft MBH lifted its position in Eli Lilly And Co by 22.5% during the first quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 149,835 shares of the company’s stock valued at $11,490,000 after acquiring an additional 27,533 shares during the last quarter. 76.58% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts recently commented on the stock. Credit Suisse Group increased their target price on shares of Eli Lilly And Co from $82.00 to $84.00 and gave the company an “underperform” rating in a research report on Thursday, June 21st. BMO Capital Markets reissued a “hold” rating and set a $79.00 target price on shares of Eli Lilly And Co in a research report on Tuesday, April 24th. Barclays set a $98.00 price target on shares of Eli Lilly And Co and gave the stock a “buy” rating in a report on Tuesday, May 22nd. Bank of America raised their price target on shares of Eli Lilly And Co from $90.00 to $94.00 and gave the stock a “neutral” rating in a report on Wednesday, July 25th. Finally, Cantor Fitzgerald set a $100.00 price target on shares of Eli Lilly And Co and gave the stock a “buy” rating in a report on Tuesday, July 24th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly And Co presently has a consensus rating of “Hold” and a consensus price target of $100.13.

In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the stock in a transaction on Tuesday, July 31st. The shares were sold at an average price of $98.74, for a total value of $20,241,700.00. Following the sale, the insider now owns 121,121,794 shares in the company, valued at $11,959,565,939.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Enrique A. Conterno sold 25,000 shares of the stock in a transaction on Thursday, May 31st. The stock was sold at an average price of $85.00, for a total transaction of $2,125,000.00. The disclosure for this sale can be found here. Insiders sold 1,735,639 shares of company stock worth $160,728,361 in the last quarter. Company insiders own 0.11% of the company’s stock.

NYSE LLY opened at $105.55 on Friday. The firm has a market capitalization of $109.82 billion, a price-to-earnings ratio of 24.65, a P/E/G ratio of 1.70 and a beta of 0.27. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $105.92. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.40 and a quick ratio of 1.09.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.20. The business had revenue of $6.36 billion during the quarter, compared to analysts’ expectations of $6.05 billion. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the company posted $1.11 earnings per share. equities analysts anticipate that Eli Lilly And Co will post 5.47 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 10th. Stockholders of record on Wednesday, August 15th will be paid a $0.5625 dividend. The ex-dividend date is Tuesday, August 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.13%. Eli Lilly And Co’s payout ratio is currently 52.57%.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: How Important is Technical Analysis of Stocks

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.